SciClone and Taiwan Liposome Company Enter Into a Licensing Agreement for ProFlow(R), a Novel Treatment for Peripheral Arterial

SciClone and Taiwan Liposome Company Enter Into a Licensing Agreement for 
ProFlow(R), a Novel Treatment for Peripheral Arterial Disease for
the China Market 
FOSTER CITY, CA and TAIPEI CITY, TAIWAN -- (Marketwired) -- 06/25/13
--   SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced
that the Company has entered into an agreement with Taiwan Liposome
Company (TLC) granting SciClone a license and the exclusive rights in
China, Hong Kong and Macau to promote, market, distribute and sell
ProFlow(R) for the treatment of peripheral arterial disease (PAD) and
other indications.  
ProFlow is a novel lipid emulsion-based formulation of prostaglandin
E1 (PGE1), a vasodilator and platelet inhibitor. TLC's proprietary
lipid-based delivery systems (LDDS) are designed to modify and
broaden the use of existing drugs and enhance their therapeutic
index. ProFlow has demonstrated to have twice the shelf life as
currently marketed lipid emulsion formulations of PGE1. A patent
providing broad protection for ProFlow has been granted in China,
Japan and Taiwan. TLC has also applied for worldwide composition of
matter patents.  
Peripheral arterial disease is a serious cardiovascular condition in
which blood flow to the limbs (usually the legs) is restricted due to
arterial plaque build-up. PAD can cause severe pain and restricted
mobility, and potentially life-threatening blood clots. PAD
represents a large and growing market opportunity in China. The
current market leading drug generates annual revenue of more than
$200 million.  
Commented Friedhelm Blobel, Ph.D., SciClone's Chief Executive
Officer: "We are excited to add ProFlow to our product portfolio, as
the cardiovascular market represents a large and growing commercial
opportunity for which SciClone is well-positioned. We can leverage
our considerable sales and marketing expertise for this product. We
believe that ProFlow has significant therapeutic and commercial
advantages that differentiate it from other branded and generic
competitors in the expanding PAD segment. We look forward to working
with our partner TLC to bring this important medical advance to
patients in need."  
"China is becoming an increasingly prominent market, and we are very
pleased to be working with a NASDAQ company that has a strong
presence in China, such as SciClone," said Dr. Keelung Hong, Chairman
and Chief Executive Officer of TLC. "SciClone was ranked number 39 in
Fortune's 2012 Fastest-Growing Companies, which makes it an ideal
partner for such a rapidly growing market like China, and also a
perfect strategic fit for TLC, since we share the same enthusiasm and
sense of urgency for bringing important new therapeutics to
Under the terms of the agreement, TLC will be responsible for the
continued development, including potential clinical trials and
regulatory activities, as well as the manufacturing and supply of
ProFlow, and SciClone will be responsible for all aspects of
commercialization, including pre- and post-launch activities. ProFlow
has been submitted to the China Food and Drug Administration (CFDA)
for approval, and it is expected that some additional clinical
testing may be required prior to approval. Financial terms of the
agreement include clinical, regulatory and sales milestone payments
up to an aggregate of $39.5 million. The agreement provides for the
principal terms of the arrangement between SciClone and TLC, and the
companies have agreed to negotiate a supplemental license and supply
About Taiwan Liposome Company 
Incorporated in 1997, Taiwan Liposome Company is a biopharmaceutical
company engaging in research, development and commercialization of
proprietary drug delivery system for improving the treatment of
cancer, ophthalmic conditions, and infectious diseases. TLC was
founded and led by renowned scientist Dr. Keelung Hong, who has over
30 years of research and development experience in liposomes with
over 100 publications. Led by Dr. Hong, TLC has a team of scientists,
management, manufacturing experts and advisors working together to
build the company into an organization recognized for its excellence
in drug delivery and rapid advancement of products. TLC currently
operates its headquarter in Taipei (Taiwan), and subsidiary offices
in South San Francisco (US) and Leiden (The Netherlands). For more
information, visit 
About SciClone  
SciClone Pharmaceuticals is a US-based, China-focused specialty
pharmaceutical company with a product portfolio of therapies for
oncology, infectious diseases, cardiovascular, urological,
respiratory, and central nervous system disorders. SciClone's
ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Besides ZADAXIN, SciClone markets about 14
mostly partnered products in China, including Depakine(R), the most
widely prescribed broad-spectrum anti-convulsant in China;
Tritace(R), an ACE inhibitor for the treatment of hypertension;
Stilnox(R), a leading hypnotic for the short-term treatment of
insomnia (marketed as Ambien(R) in the US); and Aggrastat(R), a
recently-launched interventional cardiology product. SciClone is also
pursuing the registration of several other therapeutic products in
China. SciClone is headquartered in Foster City, California. For
additional information, please visit  
Forward-Looking Statements  
This press release contains forward-looking statements. Readers are
urged to consider statements that include the words "may," "will,"
"would," "could," "should," "might," "believes," "estimates,"
"projects," "potential," "expects," "plans," "anticipates,"
"intends," "continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and
actual outcomes may differ materially. These include risks and
uncertainties relating to: the clinical trial process, including the
regulatory approval and the process of initiating trials at, and
enrolling patients at, clinical sites, to the extent required; the
effect of changes in its practices and policies related to the
Company's compliance programs. Please also refer to other risks and
uncertainties described in SciClone's filings with the SEC. All
forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements. 
Ambien, Depakine, Stilnox and Tritace are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC or Merck & Co., Inc. in
numerous other countries. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
Corporate Contacts 
Jane Green 
SciClone Investors/Media 
Paggy Liou 
Taiwan Liposome Company/Media
886 (2) 2655.7377 ext.105 
Press spacebar to pause and continue. Press esc to stop.